<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitazoxanide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitazoxanide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nitazoxanide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10105" href="/d/html/10105.html" rel="external">see "Nitazoxanide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11403" href="/d/html/11403.html" rel="external">see "Nitazoxanide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F201754"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Alinia</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048945"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiprotozoal</span></li></ul></div>
<div class="block dop drugH1Div" id="F201764"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd1ac525-b3cd-4a2a-a2c6-508340b51bda">Balantidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Balantidiasis (<i>Balantidium coli </i>infection) (alternative agent):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-AAP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to &lt;4 years: Oral suspension: Oral: 100 mg twice daily for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;12 years: Oral suspension: Oral: 200 mg twice daily for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral suspension, tablet: Oral: 500 mg twice daily for 3 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="372db3ab-3b43-4f35-80a3-de6991510623">Blastocystis, symptomatic infection with persistent diarrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastocystis, symptomatic infection with persistent diarrhea: Note:</b> Need for treatment is controversial as clinical significance of infection is unknown. Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-AAP.1','lexi-content-ref-16234044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-AAP.1','lexi-content-ref-16234044'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to &lt;4 years: Oral suspension: Oral: 100 mg twice daily for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;12 years: Oral suspension: Oral: 200 mg twice daily for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral suspension, tablet: Oral: 500 mg twice daily for 3 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b26d6aad-97f2-498c-8af8-29350debc8ca">Cryptosporidiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptosporidiosis (<i>Cryptosporidium parvum</i> infection):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment duration is 3 days in immunocompetent patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-AAP.1','lexi-content-ref-Manu.1'])">Ref</a></span>). For immunocompromised patients, including those who are HIV-exposed/-infected, suggested treatment duration is 3 to 14 days or longer, despite uncertain efficacy; HIV-infected patients should also receive optimized combination antiretroviral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to &lt;4 years: Oral suspension: Oral: 100 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;12 years: Oral suspension: Oral: 200 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral suspension, tablet: Oral: 500 mg every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2421c6ae-47fa-4c4d-b513-3b426b166737">Fascioliasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fascioliasis (<i>Fasciola hepatica; </i>sheep liver fluke infection):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to &lt;4 years: Oral suspension: Oral: 100 mg every 12 hours for 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;12 years: Oral suspension: Oral: 200 mg every 12 hours for 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral suspension, tablet: Oral: 500 mg every 12 hours for 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72c3590c-1e90-4dc5-9e62-08afccd81515">Giardiasis; independent of HIV status</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giardiasis (<i>Giardia duodenalis/intestinalis/lamblia </i>infection); independent of HIV status</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-AAP.1','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to &lt;4 years: Oral suspension: Oral: 100 mg every 12 hours for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;12 years: Oral suspension: Oral: 200 mg every 12 hours for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral suspension, tablet: Oral: 500 mg every 12 hours for 3 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="849a9db1-efd3-4017-b046-fbb3066e485d">Hymenolepiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hymenolepiasis (<i>Hymenolepis nana</i>; dwarf tapeworm infection): </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.4','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.4','lexi-content-ref-AAP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to &lt;4 years: Oral suspension: Oral: 100 mg twice daily for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;12 years: Oral suspension: Oral: 200 mg twice daily for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral suspension, tablet: Oral: 500 mg twice daily for 3 days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51131205"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51131206"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F201756"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10105" href="/d/html/10105.html" rel="external">see "Nitazoxanide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b26d6aad-97f2-498c-8af8-29350debc8ca">Cryptosporidiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptosporidiosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immunocompetent patients: <b>Oral:</b> 500 mg every 12 hours for 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with HIV (off-label use): <b>Oral:</b> 500 mg to 1 g twice daily for 14 days (must be used in conjunction with optimized antiretroviral therapy, electrolyte replacement, symptomatic treatment, and rehydration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-10326116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-10326116'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Solid organ transplant recipients (off-label use): <b>Oral:</b> 500 mg to 1 g twice daily for 14 days, in combination with reduction of immunosuppression, when possible. In patients with severe diarrhea or treatment failure, consider 500 mg twice daily in combination with azithromycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31145496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31145496'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a7088e0-7d0f-47f9-85ee-4c73938d530d">Giardiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giardiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg every 12 hours for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31145496','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31145496','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Alternative agent for solid organ transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31145496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31145496'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992018"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989268"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F201730"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&gt;2%), nausea (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Diarrhea (exacerbation), dizziness, dyspnea, gastroesophageal reflux disease, skin rash, urticaria</p></div>
<div class="block coi drugH1Div" id="F201741"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to nitazoxanide or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F201728"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• HIV: Nitazoxanide had not been studied for treatment of diarrhea caused by <i>G. lamblia</i> in patients with HIV infection. Nitazoxanide has not been shown to be superior to placebo for treatment of diarrhea caused by <i>C. parvum</i> in patients with HIV.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunocompromised patients: Nitazoxanide had not been studied for treatment of diarrhea caused by <i>G. lamblia</i> in patients with immunodeficiency. Nitazoxanide has not been shown to be superior to placebo for treatment of diarrhea caused by <i>C. parvum</i> in patients with immunodeficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F201736"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alinia: 100 mg/5 mL (60 mL) [contains fd&amp;c red #40 (allura red ac dye), sodium benzoate; strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alinia: 500 mg [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake, soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block geq drugH1Div" id="F201725"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F3422268"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Alinia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $10.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Alinia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $173.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Nitazoxanide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $165.21</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53567996"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">The oral suspension contains sucrose 1.48 g/5 mL. </p></div>
<div class="block admp drugH1Div" id="F52613427"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food. Shake suspension well prior to administration.</p></div>
<div class="block adm drugH1Div" id="F201738"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with food. Shake suspension well prior to administration.</p></div>
<div class="block sts drugH1Div" id="F201750"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Following reconstitution of oral suspension, discard unused portion after 7 days.</p></div>
<div class="block usep drugH1Div" id="F53568037"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of diarrhea caused by <i>Giardia lamblia </i>or <i>Cryptosporidium parvum</i> (Oral suspension: FDA approved in ages ≥1 year and adults; Tablet: FDA approved in ages ≥12 years and adults); has also been used for the treatment of balantidiasis, fascioliasis, and hymenolepiasis.</p></div>
<div class="block cyt drugH1Div" id="F13299763"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221927"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block foi drugH1Div" id="F201751"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases AUC. Management: Take with food.</p></div>
<div class="block dic drugH1Div" id="F201743"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some formulations may contain sucrose.</p></div>
<div class="block pri drugH1Div" id="F201742"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to the use of nitazoxanide in pregnancy is limited (Meneses Calderón 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Nitazoxanide may be used during pregnancy after the first trimester in women with severe symptoms of cryptosporidiosis (HHS [OI adult 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53568031"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor stool frequency.</p></div>
<div class="block pha drugH1Div" id="F201727"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nitazoxanide is rapidly metabolized to the active metabolite tizoxanide <i>in vivo</i>. Activity may be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism. <i>In vitro</i>, nitazoxanide and tizoxanide inhibit the growth of sporozoites and oocysts of <i>Cryptosporidium parvum</i> and trophozoites of <i>Giardia lamblia</i>.</p></div>
<div class="block phk drugH1Div" id="F201740"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Tizoxanide: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Relative bioavailability of suspension compared to tablet: 70%; tablet and suspension are not bioequivalent.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Tizoxanide: 1 to 1.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, to an active metabolite, tizoxanide. Tizoxanide undergoes conjugation to form tizoxanide glucuronide. Nitazoxanide is not detectable in the serum following oral administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Tizoxanide and tizoxanide glucuronide: 1 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~33%); feces (~67%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539902"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Nixoran</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cryptaz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alinix | Antizoa | Atinid | Dianide | Diar | Niazid | Nidor | Nidozox | Nitanid | Nitasol | Nitax | Nitazet | Nitazox | Nitide | Nixar | Nizonid | Ntz | Tazonid | Tazox | Toza | Xanita | Zoxanid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Annita | Azox | Irose | Minti | Naxxagran | Nitazoxanida | Para | Rudite | Tanisea | Trinida | Zoxylab</span>;</li>
<li>
<span class="countryCode">(BZ)</span> <span class="country">Belize</span><span class="countrySeparator">: </span><span class="drugName">Zox</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Allpar | Alpex nizox | Amezox | Biomebal | Celectan | Coluquim | Crosimpar | Desloprel | Diparfin | Droxart | Entamoxin | Flupar | Galezol | Giardameb plus | Giarfin | Givotan | Helmintaz | Imponix | Jointax | Kainol nf | Kazide | Larvisol | Loisten | Mebapar | Mixel | Nitahelmin | Nitanox | Nitaxbay | Nitaxozanida p.p.s. | Nitazer p | Nitazofin | Nitazoxanida | Nitofar | Nitoxipar | Nitxan | Nitzanid | Nizatax | Nizox | Nizuleth | Nodik | Nytax | Omnipar | Paraxin | Pranexxin duo | Proxanida | Rodanex | Souxa | Takinox | Taxanida | Taxen | Tidax | Trimebizol | Trimebizol F | Vibatrin | Xinpa | Zelix</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ambarina | Amebbil aglf | Famidox | Givotan | Neoparax | Nitacure | Nitamida | Nitaxol | Nitazofin | Nitazoxanida | Nitazoxanida mk | Nixiber | Nizonide | Nodik | Nor-Tripar | Omniparax | Paramix | Paraxin | Repinox | Takinox | Uniplus | Verfin | Xamida | Zetidim | Zoxanid</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Abanix | Celectan | Colufase | Coluquim | Kazide | Nidax | Nitaxel | Nitazofin | Nitazoxanida | Nitazoxanida mk | Nitelmin | Nizatax | Nodik | Parasinox | Paraxin | Pazidol N | Repinox | Taxanid | Tazonid</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alinia</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Antidiazox | Cryptonaz | Cryptoper | Cryptosept | Egygastreaz | Nanazoxid | Nit Clean | Nitazode | Nitazoxin | Protostop | Trustnal | Xerovirinc | Zolifutal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cryptaz</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Netazox | Nitacure | Nitadox | Nitarid | Nitazet | Nitcol | Nixide | Nizonide | Nozoa | Zimdax | Zonaxid | Zoxakind | Zstop</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Netazox | Nidozox | Nizal | Toza</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Avisan | Celectan | Daxon | Dexidex | Duplasox | Kidonax | Mitafar | Mixelim | Nitazoxanid | Nitazoxanida | Nitazoxanida Raam | Nodik | Padovanton | Paramix | Parsenida | Rosanil | Zotanixin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Netazox</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alinia</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Alinia | Nizonide</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Albazan | Bio cistenid | Celectan | Colufase | Coluquim | Coluxanida | Drexifor | Gardil | Giardil | Lumbris | Mixel | Netazox | Nitaxid | Nitaxom | Nitazine | Nitazoxanida | Nitoxadin | Nitoxin | Nixopar | Noxom | Noxzolin | Paranitaxz | Taxonide</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adnix | Atizox | Contiza | Dianitox | Diatazox | Diazox | Indomide | Izato | Liskonit | Nitabar | Nitabin | Nitacure | Nitarains | Nitazide | Nitazon | Nitazox | Nitox | Nitranex | Nitz | Nitzax | Nizonide | Therazide | Trinide</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alinia</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alinia</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alinia</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Anelmin | Anelmin 100 | Giarlam | Givotan | Nitaxo | Noxom | Parasitrin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Antidiazox | Netazox</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Nitazoxanida ion</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Celectan | Givotan | Mixel | Nitax | Nitaxolin | Nitazoxanida | Nytaxin | Phestal | Taniazin | Zoxaval</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Netazox</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Romark.1">
<a name="Romark.1"></a>Alinia tablets and oral suspension (nitazoxanide) [prescribing information]. Tampa, FL: Romark, LC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10602740">
<a name="10602740"></a>Bicart-Sée A, Massip P, Linas MD, Datry A. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. <i>Antimicrob Agents Chemother</i>. 2000;44(1):167-168. doi:10.1128/aac.44.1.167-168.2000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/10602740/pubmed" id="10602740" target="_blank">10602740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a> .<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Parasites - Balantidiasis (also known as Balantidium coli infection). <a href="https://www.cdc.gov/parasites/balantidium/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/balantidium/health_professionals/index.html</a>. Updated May 20, 2020a. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Parasites - Blastocystis spp. infection. <a href="https://www.cdc.gov/parasites/blastocystis/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/blastocystis/health_professionals/index.html</a>. Updated May 20, 2020b. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Parasites - Cryptosporidium (also known as "Crypto"). <a href="https://www.cdc.gov/parasites/crypto/treatment.html" target="_blank">https://www.cdc.gov/parasites/crypto/treatment.html</a>. Updated November 24, 2021. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.4">
<a name="CDC.4"></a>Centers for Disease Control and Prevention (CDC). Parasites - Hymenolepiasis (also known as Hymenolepis nana infection). <a href="https://www.cdc.gov/parasites/hymenolepis/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/hymenolepis/health_professionals/index.html</a>. Updated May 20, 2020c. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30753384">
<a name="30753384"></a>Gamiño-Arroyo AE, Guerrero ML, McCarthy S, et al; Mexico Emerging Infectious Diseases Clinical Research Network (LaRed). Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. <i>Clin Infect Dis</i>. 2019;69(11):1903-1911. doi: 10.1093/cid/ciz100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/30753384/pubmed" id="30753384" target="_blank">30753384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22525879">
<a name="22525879"></a>Hadad GM, Abdel Salam RA, Emara S. Validated and optimized high-performance liquid chromatographic determination of tizoxanide, the main active metabolite of nitazoxanide in human urine, plasma and breast milk. <i>J Chromatogr Sci</i>. 2012;50(6):509-515. doi:10.1093/chromsci/bms041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/22525879/pubmed" id="22525879" target="_blank">22525879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31145496">
<a name="31145496"></a>La Hoz RM, Morris MI; AST Infectious Diseases Community of Practice. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant.</i> 2019;33(9):e13618. doi:10.1111/ctr.13618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/31145496/pubmed" id="31145496" target="_blank">31145496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33031085">
<a name="33031085"></a>Meneses Calderón J, Figueroa Flores MDR, Paniagua Coria L, et al. Nitazoxanide against COVID-19 in three explorative scenarios. <i>J Infect Dev Ctries</i>. 2020;14(9):982-986. doi:10.3855/jidc.13274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/33031085/pubmed" id="33031085" target="_blank">33031085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10326116">
<a name="10326116"></a>Rossignol JF, Hidalgo H, Feregrino M, et al. A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. <i>Trans R Soc Trop Med Hyg</i>. 1998;92(6):663-666. doi:10.1016/s0035-9203(98)90804-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/10326116/pubmed" id="10326116" target="_blank">10326116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234044">
<a name="16234044"></a>Rossignol JF, Kabil SM, Said M, Samir H, Younis AM. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. <i>Clin Gastroenterol Hepatol</i>. 2005;3(10):987-991. doi:10.1016/s1542-3565(05)00427-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/16234044/pubmed" id="16234044" target="_blank">16234044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24569199">
<a name="24569199"></a>Siberry GK, Abzug MJ, Nachman S, et al; Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <i>Pediatr Infect Dis J</i>. 2013;32(suppl 2):i-KK4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/24569199/pubmed" id="24569199" target="_blank">24569199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Updated May 26, 2020. Accessed November 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed October 5, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12904 Version 189.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
